Clinical trials: Prostate Cancer Stage
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
- Trial name
- NCT04666129
- Testing
- Relugolix, Abiraterone, Prednisone
- Where
- 16 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Prostate Cancer
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine plus paclitaxel in treating patients with…
- Trial name
- NCT00003622
- Testing
- paclitaxel, vinorelbine tartrate
- Where
- United States
- Sponsor
- James Ahlgren
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Prostate Cancer
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
- Trial name
- NCT02107391
- Testing
- Dendritic Cells DCVAC/PCa, Leuprolide acetate, Goserelin Acetate
- Where
- 9 sites in Czechia
- Volunteers
- 63 people
- Sponsor
- SOTIO a.s.
Prostate Cancer
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16…
- Trial name
- NCT00349557
- Testing
- bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Benaroya Research Institute
Prostate Cancer Metastatic
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
The purpose of this study is to evaluate the incidence of grade ≥ 3 neutropenia and/or neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of cabazitaxel (bi-weekly versus tri-weekly) plus…
- Trial name
- CABASTY (NCT02961257)
- Testing
- cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
- Where
- 31 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Prostate Cancer
Digoxin for Recurrent Prostate Cancer
The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time).
- Trial name
- NCT01162135
- Testing
- Digoxin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Castration-resistant Prostate Cancer Patients with Oligometastases
Management of Castration-Resistant Prostate Cancer with Oligometastases
This adaptive phase II/III randomized trial is designed to demonstrate that eradication of oligometastases by SBRT is a promising and emerging way to delay disease progression and postpone second line systemic therapies in…
- Trial name
- PCS IX (NCT02685397)
- Testing
- Leuprolide Acetate, Goserelin Acetate, Triptorelin
- Where
- 11 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006114
- Testing
- mitoxantrone hydrochloride, vinorelbine tartrate
- Where
- 10 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Castration-resistant Prostate Cancer
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in…
- Trial name
- RAD402 (NCT07259213)
- Testing
- 161Tb RAD402
- Where
- 2 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Radiopharm Theranostics, Ltd
Prostate Cancer
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00004124
- Testing
- bicalutamide, goserelin, mitoxantrone hydrochloride
- Where
- 234 sites in United States
- Volunteers
- 983 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate
Docetaxel and Lycopene in Metastatic Prostate Cancer
Docetaxel is the standard, first-line chemotherapeutic agent for castrate resistant prostate cancer. While it has clinically useful activity, there is a strong need for substantial improvement in its efficacy.
- Trial name
- NCT01949519
- Testing
- Lycopene and Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer
The purpose of this study is to evaluate the effects of Noni extract in men diagnosed with very low risk or low risk prostate cancer
- Trial name
- NCT02648919
- Testing
- Noni extract
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Hawaii
Prostate Cancer
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of…
- Trial name
- PICT-01 (NCT04009967)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells.
- Trial name
- NCT00006002
- Testing
- dexamethasone, semaxanib
- Where
- 18 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Prostate Cancer
Positron Emission Tomography in Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
- Trial name
- NCT00121212
- Testing
- carbon-11 acetate PET scan
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer, Advanced Prostate Carcinoma
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
This clinical trial explores and implements methods to improve informed decision making (IDM) regarding precision oncology tests amongst veterans with prostate cancer that may have spread from where it first started to nearby…
- Trial name
- NCT05396872
- Testing
- Participant Surveys, Mobile app
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Francisco
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.